Viking Therapeutics Q2 net loss widens, misses expectations

Viking Therapeutics

23/07/2025 21:35

Overview

Viking Therapeutics Q2 net loss of $65.6 mln misses analyst expectations

EPS for Q2 misses estimates due to higher R&D and admin expenses

Company maintains strong cash position of $808 mln to support clinical trials

Outlook

Company expects top-line results from VENTURE-Oral study in 2H25

Viking plans IND submission for DACRA program in 4Q25

Amylin program IND filing expected in Q4 2025

Result Drivers

PHASE 3 TRIALS - Initiation of Phase 3 VANQUISH trials for VK2735 in obesity and type 2 diabetes

PHASE 2 ENROLLMENT - Completion of enrollment for Phase 2 VENTURE-Oral Dosing trial

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Miss
-$0.58
-$0.45 (19 Analysts)
Q2 Net Income
Miss
-$65.56 mln
-$51.60 mln (16 Analysts)
Q2 Income from Operations
Miss
-$74.57 mln
-$59.10 mln (15 Analysts)
Q2 Operating Expenses
$74.57 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Viking Therapeutics Inc is $101.00, about 68.2% above its July 22 closing price of $32.10

Press Release: ID:nPn9SCNZpa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)